Role of sildenafil in melanoma incidence and mortality
Menée aux Etats-Unis auprès de 25 848 participants (durée de suivi : 10 ans), cette étude prospective évalue l'association entre l'utilisation du sildénafil (Viagra) et le risque de mélanome (142 cas de mélanome, 580 cas de carcinome épidermoïde, 3 030 cas de carcinome basocellulaire)
In 2014, about 76 100 new melanomas will be diagnosed, and an estimated 9710 persons will die (about 6470 men and 3240 women).1 Patients with melanoma in situ, stage 0, have a 5-year survival rate of 99% when treated with excision, whereas those with melanoma limited to the skin and with a tumor thickness of 2.01 to 4.0 mm, stage II B, have a 5-year survival rate of about 57%. Patients with metastatic melanoma, stage IV, have a 5-year survival rate of 15% to 20%. Despite newly available targeted agents, systemic therapies rarely lead to cures. These sizable survival differences illustrate the need for early detection of melanoma; early detection of primary melanomas followed by surgical excision remains critical.